Step Therapy

What Is Step Therapy?

Step therapy, sometimes called a fail-first protocol, is a type of prior authorization used by health plans and pharmacy benefit managers to control prescription drug costs. Under a step therapy rule, a member must first try a designated first-line medication, usually a lower-cost generic or preferred brand, and show that it does not adequately treat their condition before the plan will approve a more expensive second-line drug.

Step therapy sits within the broader discipline of utilization management, alongside prior authorization and utilization review, and is most common for high-cost drug categories such as biologics, specialty medications, and treatments for chronic conditions like rheumatoid arthritis or psoriasis. Health plans build step therapy rules into their formulary, and providers submit documentation showing a patient met, or should be exempted from, the first-line requirement. When that documentation is incomplete, it becomes a common source of friction in care management.

Why It Matters

Step therapy directly affects both drug spend and patient outcomes, which makes it one of the more closely watched levers in pharmacy benefit management. Used well, it steers members toward proven, affordable therapies first and reduces waste on expensive drugs that may not be the best clinical fit. Used poorly, or without a fast exception process, it delays treatment for patients who need the second-line drug immediately, creating complaints, provider friction, and appeal volume.

For health plans, the operational stakes are as high as the clinical ones. Every determination requires accurate benefit configuration, timely review of exception requests, and clear communication to prescriber and member, or the delay itself becomes the compliance and satisfaction risk. The administrative weight is significant: physicians and their staff report spending close to 16 hours per week on prior authorization and step therapy requirements, per an American Medical Association survey cited in Firstsource's analysis.

How Step Therapy Works

1. Formulary rule design: The health plan or PBM designates which drugs sit at step one and which require prior failure before step two.
2. First-line prescription and trial: The prescriber starts the patient on the required first-line medication for a clinically appropriate trial period.
3. Outcome documentation: The prescriber records whether the drug worked, caused side effects, or was contraindicated, and submits this evidence to the plan.
4. Exception request and review: If the patient cannot safely try the first-line drug, the prescriber can request an exception, which the plan reviews against clinical criteria.
5. Coverage determination and appeal rights: The plan approves or denies the second-line drug, and members retain the right to appeal a denial through appeals and grievances.

Regulatory and Compliance Considerations

Most US states now have step therapy override laws that require health plans to grant an exception within a set timeframe, often 24 to 72 hours for urgent requests, when a prescriber shows the first-line drug already failed, is expected to fail, or would cause harm. These laws vary by state in the conditions they cover, the required response time, and the documentation a plan can request, which makes step therapy one of the more state-specific corners of utilization management to administer nationally.

For Medicare Advantage plans, the Centers for Medicare & Medicaid Services requires that step therapy programs for Part B drugs include a clear appeals process and that plans respond within specific timeframes, typically 24 hours for expedited requests and 72 hours for standard ones. Plans that miss these windows risk compliance findings during CMS audits and Star Ratings penalties tied to member experience.

Commercial plans face similar pressure from state insurance regulators and employer groups, who scrutinize step therapy protocols during renewal negotiations. The operational answer is the same regardless of line of business: a step therapy program is only as compliant as its exception-handling infrastructure. Plans that route exception requests through a dedicated, tracked workflow, rather than a general prior authorization queue, show faster turnaround and fewer escalations. Documentation quality is decisive: requests that clearly link back to medical necessity criteria move through review far faster than those that simply state a preference.

Communication during the exception window matters as much as review speed. A plan that processes a request quickly but fails to notify the pharmacy or member promptly can still produce a delay at dispensing. Automated status notifications, so the pharmacy and prescribing office both see a real-time update the moment a decision is issued, close this last-mile gap.